目的：观察自体DC联合CIK细胞治疗晚期乳腺癌患者的安全性及临床疗效，并分析相关预后因素。方法： 回顾性分析2011年8月至2014年12月在解放军第81医院进行DC-CIK细胞治疗的42例晚期乳腺癌患者临床资料，采用实体瘤疗效评价标准评价近期疗效，并观察DC-CIK细胞治疗的安全性。分析患者生存期，评价远期疗效，单因素及多因素分析预后因素，并采用配对t检验分析患者治疗前后免疫功能。结果： 42例晚期乳腺癌患者经DC-CIK细胞治疗后，客观缓解率为38.1%(16/42)，疾病控制率为61.9%(26/42)；1年生存率为59%，2年生存率为48%，3年生存率为48%；肿瘤标记物CA153治疗后显著性降低；外周血淋巴细胞亚群除辅助性T细胞（CD3+CD4+）水平显著性升高外，其他淋巴细胞亚群无显著性变化。单因素分析结果显示，肿瘤部位（P=0.012）、治疗前CA153水平（P=0.000）是DC-CIK细胞治疗预后的影响因素；多因素分析结果显示，治疗前CA153水平（P=0.003）是DC-CIK细胞治疗的独立预后因素。结论： 晚期乳腺癌患者经DC-CIK细胞治疗后，无明显不良反应，可能提高患者长期生存率，产生临床获益，安全可行。

Objective:To evaluate the clinical efficacy and safety of dendritic cells (DCs) combined with cytokine-induced killer (CIK) cells in the treatment of advanced breast cancer, and to investigate the relevant prognostic factors. Methods: The clinical documents of 42 patients with advanced breast cancer that received DC/CIK treatment in 81st Hospital of PLA from August 2011 to December 2014 were retrospectively analyzed. Short-term curative effect was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) and the safety of DC-CIK therapy was observed. Overall survival of 42 patients was analyzed to evaluate the long-term curative effect. Univariate and multivariate analyses were used to analyze prognostic factors. The immunologic function was evaluated by paired T-test. Results: After the DC-CIK therapy, the overall response rate was 38.1% (16/42), the disease control rate was 61.9% (26/42), and the one-year, two-year and three-year survival rates were 59%, 48% and 48%, respectively. CA153 was significantly decreased after the treatment. In addition to a significant increase in the CD4+ level, the other peripheral blood lymphocyte subsets didn’t change significantly. Univariate analysis showed that the onset area (P=0.012) and the CA153 value before treatment (P=0.000) were the influence factors for the prognosis of cell immune therapy. Multivariate analysis showed that the CA153 value before treatment was an independent influence factor for the prognosis of cell immune therapy. Conclusion: The DC-CIK therapy is a safe and feasible therapeutic approach. It may improve the long-term survival rate of patients with advanced breast cancer.

南京军区医学科技创新项目资助（No.14MS052）